https://academic.oup.com/bjs/article/109/2/147/6438058?login=false
With recently demonstrated success with Remestemcel-L, I imagine access costs would reduce due to increase of demand for the therapy. Plus costs of MSCs & cost to patient quality of life & ongoing care needs to also be factored in.
Another Mesoblast future success!
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-12955
-
- There are more pages in this discussion • 5,063 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.00 |
Change
-0.010(0.99%) |
Mkt cap ! $1.158B |
Open | High | Low | Value | Volume |
$1.02 | $1.02 | $1.00 | $1.600M | 1.586M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 101550 | $1.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.01 | 75500 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
35 | 83648 | 1.005 |
18 | 184633 | 1.000 |
12 | 251610 | 0.995 |
9 | 542604 | 0.990 |
4 | 31677 | 0.985 |
Price($) | Vol. | No. |
---|---|---|
1.010 | 85623 | 26 |
1.015 | 96217 | 13 |
1.020 | 240432 | 20 |
1.025 | 104652 | 8 |
1.030 | 55189 | 2 |
Last trade - 14.58pm 19/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |